NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $1.03 -0.02 (-1.90%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cognition Therapeutics Stock (NASDAQ:CGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$1.01▼$1.0550-Day Range$0.89▼$1.1752-Week Range$0.55▼$2.67Volume377,455 shsAverage Volume1.11 million shsMarket Capitalization$97.94 millionP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingModerate Buy Company Overview Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease. CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease. In addition to its lead program, the company is advancing a preclinical pipeline aimed at expanding its approach to other neurodegenerative conditions. To support its global development efforts, Cognition Therapeutics collaborates with academic centers, contract research organizations and specialized clinical sites. Headquartered in Pittsburgh, Pennsylvania, Cognition Therapeutics conducts operations primarily in the United States, with ongoing clinical and regulatory activities in European markets. The company is led by co-founder and CEO Stephen M. Maccecchini, Ph.D., who oversees research, development and strategic partnerships. Cognition Therapeutics’ common stock is traded on the NASDAQ under the ticker symbol CGTX.AI Generated. May Contain Errors. Read More Cognition Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCGTX MarketRank™: Cognition Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 636th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCognition Therapeutics has a consensus price target of $3.33, representing about 223.6% upside from its current price of $1.03.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.43% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 10.05, which indicates bearish sentiment.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 20.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cognition Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Stock News HeadlinesCognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 29, 2026 | americanbankingnews.comCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comThe ultimate IPO unicorn before Labor DayAnthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports.September 4 at 1:00 AM | Weiss Ratings (Ad)Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside DiscussionJuly 13, 2026 | quiverquant.comQCognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision SummitJuly 13, 2026 | globenewswire.comCognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks RemainJune 27, 2026 | seekingalpha.comCognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33%June 24, 2026 | msn.comCognition Therapeutics advances after FDA supports key elements of pivotal trial plan (CGTX)June 24, 2026 | msn.comSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.35 at the start of the year. Since then, CGTX stock has decreased by 23.7% and is now trading at $1.03. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an IPO on Thursday, October 7th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Top institutional shareholders of Cognition Therapeutics include BlackRock Inc. (1.41%), Sigma Planning Corp (0.38%), Tocqueville Asset Management L.P. (0.36%) and Texas Capital Bank Wealth Management Services Inc (0.16%). Insiders that own company stock include Lisa Ricciardi and John Brendan Doyle. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS). Company Calendar Last Earnings8/06/2026Today9/04/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CGTX's financial health is in the Yellow zone, according to TradeSmith. CGTX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CGTX CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees20Year Founded2007Price Target and Rating Average Price Target for Cognition Therapeutics$3.33 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+223.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.17% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.94Miscellaneous Outstanding Shares95,090,000Free Float84,529,000Market Cap$97.94 million OptionableNot Optionable Beta1.79 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CGTX) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersCongress Just Opened the FloodgatesThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredNear retirement? Buy this stockOn August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...Stansberry Research | SponsoredTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | SponsoredThis Overlooked Fund Turns AI Stocks Into Weekly IncomeA small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts